Format
Sort by

Send to

Choose Destination

Search results

Items: 3

1.

Novel ligands balance estrogen receptor β and α agonism for safe and effective suppression of the vasomotor response in the ovariectomized female rat model of menopause.

McGregor C, Sau A, Ruddy SC, Leung D, Webb M, Durst T, Wright JS, Lagace D, Pratt MA.

Endocrinology. 2014 Jul;155(7):2480-91. doi: 10.1210/en.2013-1976. Epub 2014 May 13.

PMID:
24823389
2.

Preferential estrogen receptor β ligands reduce Bcl-2 expression in hormone-resistant breast cancer cells to increase autophagy.

Ruddy SC, Lau R, Cabrita MA, McGregor C, McKay BC, Murphy LC, Wright JS, Durst T, Pratt MA.

Mol Cancer Ther. 2014 Jul;13(7):1882-93. doi: 10.1158/1535-7163.MCT-13-1066. Epub 2014 Apr 30.

3.

A-CD estrogens. I. Substituent effects, hormone potency, and receptor subtype selectivity in a new family of flexible estrogenic compounds.

Wright JS, Shadnia H, Anderson JM, Durst T, Asim M, El-Salfiti M, Choueiri C, Pratt MA, Ruddy SC, Lau R, Carlson KE, Katzenellenbogen JA, O'Brien PJ, Wan L.

J Med Chem. 2011 Jan 27;54(2):433-48. doi: 10.1021/jm100513m. Epub 2010 Dec 29.

PMID:
21190382

Supplemental Content

Loading ...
Support Center